Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.47 |
| ▸ | PIM1 | P11309 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ETV6 | P41212 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398645 | 0.85 | LRRK2 (0.42) | LRRK2KDR | |
| SCHEMBL1558859 | 0.82 | DGAT1 (0.45) | CNR2LRRK2MAPK1KDRETV6 | |
| SCHEMBL2395253 | 0.78 | DYRK1A (0.46) | LRRK2PIM1 | |
| SCHEMBL2396513 | 0.77 | LRRK2 (0.53) | LRRK2PIM1KDRETV6 | |
| SCHEMBL2396142 | 0.76 | PIM1 (0.38) | LRRK2PIM1MAPK1KDR | |
| SCHEMBL14098982 | 0.75 | LRRK2 (0.55) | CNR2LRRK2MAPK1KDRETV6 | |
| SCHEMBL1559214 | 0.74 | MAPK10 (0.46) | LRRK2MAPK1KDR | |
| SCHEMBL1557449 | 0.74 | LRRK2 (0.42) | LRRK2PIM1MAPK1ATR | |
| SCHEMBL1558709 | 0.74 | NPBWR1 (0.46) | — | |
| SCHEMBL2395588 | 0.73 | ACVR1 (0.44) | CNR2LRRK2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PIK3CA, AKT1, PIK3R5 | CNR2 2414/4885LRRK2 372/4885PIM1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.